Life sciences partner Greg Levine (Washington, D.C.) was quoted in a Nov. 10 Bloomberg BNA Health Care Daily Report article on the drug industry possibly facing less scrutiny under President-elect Donald Trump and the new U.S. Congress.
Mr. Levine expects staff turnover in key leadership positions at the U.S. Food and Drug Administration along with expedited drug approvals and reduced regulatory burdens for the life sciences industry. A more conservative U.S. Supreme Court is likely to continue the trend of extending First Amendment protections to commercial speech including manufacturers’ ability to disseminate information about unapproved or off-label uses of products. However, Trump’s tough stance on trade issues with China and other countries could also have negative repercussions for the drug industry.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.